Researchers in Japan have developed a personalized mRNA vaccine that shows promise for treating recurrent gastric cancer, specifically peritoneal metastasis, which is often difficult to manage with existing therapies. This study, published in Inside Precision Medicine, involved a collaborative effort to create a lipid nanoparticle (LNP)-encapsulated mRNA vaccine that encodes three unique neoantigens derived from a specific gastric cancer cell line. The vaccine was tested alongside anti-PD-1 therapy in mouse models to assess its effectiveness.
Neoantigens are unique targets on tumor cells that arise from individual genetic mutations, making them key components of personalized cancer immunotherapy. The focus on peritoneal metastasis is significant, as this recurrence route is associated with poor patient outcomes and limited response to current treatments like nivolumab combined with chemotherapy.
The researchers synthesized the mRNA vaccine and found that it induced a higher frequency of neoantigen-specific CD8⁺ T cells compared to traditional dendritic cell-based vaccines. In experiments, the mRNA vaccine not only led to tumor regression but also completely eradicated tumors in all treated mice, especially when combined with anti-PD-1 therapy.
One of the notable findings was the vaccine’s ability to prevent recurrence of gastric cancer. When administered prophylactically, it successfully inhibited peritoneal metastasis. Therapeutically, the combination of the mRNA vaccine and anti-PD-1 treatment significantly suppressed tumor growth in established metastases. This combination therapy was effective because it increased both progenitor and exhausted T cells, which are crucial for sustaining an immune response.
While the results are promising, they were based on a specific murine model, and further validation in other models is needed. The researchers emphasized the challenge of identifying the neoantigens that T cells recognize in vivo. This study builds on previous research showing that mRNA vaccines targeting patient-specific neoantigens can provoke strong antitumor responses, supporting the exploration of such vaccines in other metastatic conditions.
Future research may focus on combining this mRNA vaccine platform with other agents to enhance its effectiveness against the immune suppression often seen in peritoneal metastases.
